Purpose: To provide a validated method to confidently identify exon-containing copy number variants (CNVs), with a low false discovery rate (FDR), in targeted sequencing data from a clinical laboratory with particular focus on single-exon CNVs.
INTRODUCTION
Copy number variation (CNV) is an important feature of the human genome and can confer disease susceptability [1] [2] [3] [4] . The ability to detect CNVs accurately is critical for both genetic diagnostics and to advance understanding their impact on gene function. Next-generation sequencing (NGS) based targeted gene panels are commonly used in clinical genetic testing and various methods [5] [6] [7] [8] [9] [10] [11] [12] [13] have been developed to identify exonic CNVs in gene panel sequence data. Gene panels afford a qualitatively different opportunity to assess small CNVs due to their typically deeper sequence coverage when compared with Whole Genome or Exome Sequencing (WES). Ideally, the methods would detect single-exon CNVs, but this is challenging because a single exon represents one data point, which must exhibit minimal noise and maximal signal compared to multi-exonic CNVs which has corroborating data points. Detecting and reporting CNVs in the clinical context is another challenge as false positives (FPs) must be minimized, while true positives (TPs) are all identified. Achieving the high accuracy required for clinical applications invariably demands validation on alternative platforms, which bears its own set of technical challenges.
Existing CNV tools that have been validated for the clinical setting include VisCap 5 , CoNVaDING 10 , and DeCON 11 , ExomeDepth 12 , and others 6, 7, 13, 14 . CoNVaDING and ExomeDepth are methods which are successful at detecting single-exon CNVs by evaluating individual exon suitability for variant detection and selecting highly correlated samples as reference controls. In these methods, however, each single-exon CNV is treated equally and there is no mechanism to evaluate the confidence of the call. VisCap has relied on human visual scoring to reduce FPs and evaluate small CNVs.
The Electronic Medical Records and Genomics (eMERGE) Network provides an opportunity to develop tools addressing these challenges. Briefly, eMERGE Phase III is the continuation of a NIH program which aims to incorporate genomic information into medical records (25,000 participants) by identifying rare genetic variants using eMERGESeq (targeted gene panel), and their effects in 109 clinically relevant genes, including the ACMG 15 56 medically actionable genes. Here, we present Atlas-CNV, a method to identify CNVs even at the single exon level based on the normalized coverage among samples but constrained to the same capture experiment. We incorporate standard deviation (StDev) thresholds to remove low quality exons and samples for controlling FPs. Atlas-CNV produces graphical gene and exon bar plots to allow for visualization by clinicians and diagnosticians. The leveraging of the Cscoring exons to prioritize high quality single-exon CNVs enables significant reduction of FPs and obviates much of the need for costly expert-based validation and reviewing. Atlas-CNV can analyze NGS targeted gene data from a batch of multiplexed samples in a single probe-hybridization capture experiment undergoing identical conditions, which eliminates the need to sequence control samples. This is defined as a midpool experiment which is typically optimized to contain 45-48 samples. Overall, Atlas-CNV is a fast (<2 min per midpool on a single CPU core) and versatile CNV calling method that can be easily integrated into clinical diagnostic pipelines.
We benchmarked and validated Atlas-CNV on known CNVs previously identified by WES and chip array, demonstrated the exon C-scoring feature through simulation on a subset of eMERGESeq samples (sequenced at the Baylor College of Medicine Human Genome Sequencing Center), and assessed its performance by verifying 64 and 29 multi and singleexon CNVs respectively through MLPA. Currently, while eMERGE reports CNVs spanning two or more contiguous exons, our findings support the feasibility of including single-exon CNVs into medical records with the potential for increased diagnostic yield 16 .
MATERIALS AND METHODS
(Z-score at 1.96). Then, log2 scores of the sample/median ratio are computed accordingly for all exons on all samples as shown in Figure 1B . To assess sample quality, we define a SampleQC with two components: (1) a 0.2 threshold on the StDev of log2 scores for the sample, and (2) a one-way ANOVA F-test at 5% significance applied on the mean RPKM coverage between midpool samples. If either component is not satisfied, the sample is labelled 'Fail'. The former is determined by computing the StDev at each exon in one theoretical sample containing exactly two allelic copies at every exon in a simple computation where noise was randomly introduced into the sample/median ratio in 5% increments. Assuming a panel of 2000 target exons, we observed that a StDev=0.2 would correspond to approximately 25% variability in the given sample. A midpool with numerous samples failing the SampleQC would indicate a departure of sample uniformity and possible errors in the workflow (Supplementary Figure S1 ).
Exon Quality and Calling exonic CNVs
As illustrated in Figure 1B , we also use log2 scores to assess exon quality because having even-exon normalized coverage is essential to reduce FPs. Thus, we remove outliers where coverage exceeds a threshold based upon the StDev of log2 scores at a given exon (EStDev) which is calculated on midpool samples. Figure S2 ). The typical exon fail rate in a given midpool is 0.5%.
To call CNVs, we apply two thresholds on the log2 scores ( Figure 1C) ; (1) a userconfigurable hard limit of -0.6 for losses and 0.4 for gains, and (2) a soft threshold derived from the data distribution using a Z-score cutoff at 99% (z=2.576), intended as a boundary to threshold calls at the distribution tail. Any log2 score exceeding both thresholds are called CNVs. Autosomes and sex chromosomes are analyzed separately using a sample file to define the midpool or gender sub-groupings.
Visualization and Confidence Score
For visualization, Atlas-CNV produces a sample gene plot with bars representing exons, and also sectioned exon bar plot(s) to display the context of the exonic CNV with all midpool samples. In the latter, the median sample is designated as blue, the test as red, and other samples in grey. An example of a heterozygous CNV loss on 2 contiguous exons in CFTR is shown in Figure 1C .
We define a Confidence Score (C-score) to assign each exonic CNV call (positive and negative scores for duplications and deletions respectively) and suggest three categories:
"duplication or deletion", "likely duplication or deletion", "uncertain duplication or deletion" with ranges to denote copy number ( Supplementary Material Tables 1-3) . Cscores are analogous to Z-scores from the standard normal distribution, where we rescale each exon to unit variance by dividing the individual log2 score by the EStDev, with an important caveat that assumes the mean log2 scores for the given midpool is zero (or diploid). C-scoring standardizes exons on the same comparative scale. For CNVs spanning multiple exons on the same gene, an average of the individual C-scores of the CNV is reported on the gene plot.
Performance Measures and MLPA
To assess performance, we used samples with CNVs previously identified by WES, and Illumina HumanExome-12v array as our gold standard (GS). We define Sensitivity as the As our confirmation platform for detected CNVs, we performed MLPA experiments using kits purchased from MRC Holland (www.mlpa.com) for available genes. Samples were processed according to vendor protocols in batches using three controls: NA12878, NA12891, NA12892.
RESULTS

Performance Assessment and Comparison
In order to assess Atlas-CNV performance and comparisons to VisCap, we selected 13 clinical samples with a heterozygous gene deletion previously identified by WES and the Illumina HumanExome-12v array as our gold standard (Table 1) . Generally, the samples were sequenced in triplicates and divided into technical and biological replicates. The technical replicates use aliquots from the same capture experiment for sequencing while the biological replicates (2 samples: 1-100155, 12-100189) are completely distinct experiments. To compute performance measures, we averaged the replicates of each sample's comparison to the gold standard and report an overall mean of these 13 samples as bars in Figure 2 . We observed high sensitivity and specificity (>99%) across technical and biological replicates, but VisCap has lower precision (80%) and higher FDR (20%) than Atlas-CNV (95%, 4%) which can be attributed to filtering FPs by ExonQC. The legitimacy of filtered FPs was confirmed by their absence in WES data. We also observed that the average EStDev is nearly twice as large in FP calls (EStDev = 0.14 on 45 calls) compared to TP calls (EStDev = 0.079 on 1137 calls).
For reproducibility, pairwise comparisons of replicates were first averaged per sample and then the 13 means were averaged and reported. For the two samples with additional distinct experiments, 3 representative pairwise comparisons were chosen beforehand as the biological replicates (first sample of the technical replicate set), while the remaining 12 comparisons were treated as technical replicates. We report a higher reproducibility in Atlas-CNV (92%) compared to VisCap (80%) indicating ExonQC may be filtering unrepeated calls in replicate runs.
We estimated an FDR based on p-values from C-scores without prior knowledge of the truth set to confirm the Atlas-CNV FDR of 4%. Using a robust FDR routine under the assumption of a one-sided test 19 , we computed the estimated FDR for the 13 gold standard samples in the range between 0.12 to 14% for technical replicates, and 0 to 15% for biological replicates at p-value cutoffs between 0.009 to 0.01. Although the estimated range is broad, our reported FDR of 4% is within this range of 0-15% and suggests the utility of the procedure on prospective samples without orthogonal confirmation.
Analysis of eMERGE samples
We analyzed 10,926 eMERGESeq samples from 233 midpools (excluding PMS2 20 Second, we focused on single-exon detection and initially observed significant discrepancies in the number of these calls. First, Atlas-CNV called nearly 5 times fewer single-exon CNVs than VisCap (2240 vs. 10417; dels=861:5213, dups=1379:5204), and second CoNVaDING, a tool developed for single-exon detection, called even fewer than Atlas-CNV (685; 514 dels, 171 dups). Thus, to reduce the complexities of these comparisons and obtain an estimate of the FDR, we counted the number of single-exon CNVs present in >1% of samples which we assume would likely be artifacts or common CNVs. We report 85% (8818/10417) of VisCap calls, which is observed in only 10 exons, exist in >1% of the samples; 5% (114/2240) for Atlas-CNV (1 exon); and 0% (0/685) for CoNVaDING. This highlights the importance of having a mechanism to automatically filter low quality exons to reduce FPs (present in Atlas-CNV and CoNVaDING but not VisCap). In contrast, if we focus on calls in <1% of the samples (Atlas-CNV:2126, VisCap:1599, CoNVaDING:685) which are more likely to be TPs, our results show 46% (or 741/1599) of VisCap and 42% (or 286/685) of CoNVaDING calls are in common with Atlas-CNV. While the concordance is low, closer examination revealed that missed calls were labelled as multi-exon CNVs in Atlas-CNV or failed to meet the Atlas-CNV passing criteria for either an exon or sample (ExonQC or SampleQC). For example, 58% (or 395/685) of CoNVaDING calls either failed the Atlas-CNV ExonQC (6) or SampleQC (324), were labelled as multi-exon CNVs (47), or flagged as FPs (18), leaving only 4 real missed calls. A similar outcome was observed in the VisCap comparison, but only 15% of calls failed an Atlas-CNV quality control QC (225) or were labelled as multi-exon CNVs (8) , leaving 39% of calls as truly missed (or 625/1599).
Further examination of the common calls also showed CoNVaDING with a higher mean Cscore (7.11 vs 4.9) and lower mean EStDev (0.11 vs 0.14) than VisCap. Figure 3 summarizes the overall Atlas-CNV analysis. It includes results for PMS2 and X chromosome genes, which the former may require further analyses 20 . 345 samples were identified (172 losses, 173 gains) for multi-exonic CNVs which represents an overall frequency of 3.2% (1.57% losses, 1.58% gains), or 0.03 CNVs/sample. Adding high confidence single-exon CNVs (abs(C-score) >=8) marginally increases the frequency to 4.36% (1.0% losses [109], 0.20% gains [22]). As a relative comparison, the CNV frequency in ExAC 21 is 1.43%. Interestingly, we detected CNVs in 41 of the 58 ACMG genes (excluding ATP7B) with the highest occurrence in OTC (24) and GLA (24) while CNVs were observed in 38 of 51 non-ACMG eMERGE genes with KCNE1(18) and SLC25A40(11) as top genes.
Evaluation of C-score threshold for CNV calling
Across all samples, a total of 2475 exons (on average 11 exons/midpool) were removed by exon filtering with an average EStDev=0.36 compared to the 2240 passing exons with a much lower average EStDev=0.13. We report an average eFDR of 3.14% across all samples, which coincides with the FDR (4%) reported in the performance assessment study ( Figure 2 ). However, even with low EStDev and FDR, there is still a 10-fold enrichment of single over multi-exon CNVs (2240/232). Therefore, we set out to determine whether C-scores could be used as a secondary assessment of confident of single-exon CNVs primarily on the basis that standalone log2 scores do not account for the exon variability whereas C-scores are standardized by this exact variance. First, we computed the expected EStDev in a simulation of log2 scores by adding 5% increments of variability into the S/M ratio (Supplementary Figure S3 ). We determined EStDev at 0.8, 0.13 and 0.16 correspond respectively to 10%, 15% and 20% variability. Therefore, for both eMERGESeq (mean EStDev=0.92) and gold standard assessed samples (mean EStDev=0.079), the multi-exonic CNVs fall in the 10% noise range.
However, eMERGE single-exon CNVs (2240) with nearly twice the mean EStDev (0.14), fall over the >15% noise range (Supplementary Figure S4) . Therefore, to control single-exon FPs, both the log2 scores and EStDev should be utilized.
We performed a simulation of single-exon deletions to obtain C-score thresholds for optimal sensitivity. Briefly, 100 random samples were chosen from 59% (6,413/10,926) of eMERGESeq samples with no previous single-exon deletion. Each sample was randomly assigned a single-exon deletion by artificially downsizing the read depth by 5% increments from 30% to 50%. The mean C-score and sensitivity were calculated at each coverage increment and plotted on a curve (Supplementary Figure S5 ). We iterated this analysis using three calling thresholds of -0.4, -0.5, and -0.6 (default), and for all instances in the simulation study, we noted the following: (1) EStDev range 0.08-0.09, (2) eFDR range 3-
3.2%, (3) specificity >99%, and most importantly, (4) sensitivity >90% on C-scores >10
where read depth is reduced by >40%. We conclude that these observed ranges for C-score and EStDev are conservative for calling confident single-exon CNVs. When we applied a C-score=>8 and EStDev<=0.1 criteria on eMERGE samples, we identified 79 candidate singleexon CNVs (candidates for MLPA validation) which represents a 28-fold decrease from the total of 2240 identified single-exon CNVs. Notably, VisCap and CoNVaDING called 62 and 69 respectively out of these 79.
MLPA confirmation of CNVs
Sixty-four multi-exon CNVs (34 losses, 30 gains; mean C-score=9.4, EStDev=0.087) called by Atlas-CNV were selected for MLPA confirmation ( Supplementary Table S4 ). Although MLPA has its own technical limitations, using it here as the truth set we confirmed 55 CNVs with Atlas-CNV having higher sensitivity (88.8%) and lower FDR (25.0%) compared to VisCap (86.8% and 33.6% respectively). Notably, two confirmed CNVs (Vanderbilt-23 and Columbia-29) were missed by VisCap. The 9 unconfirmed CNVs were compared to the 55 confirmed CNVs and found to have significantly (1) MLPA was also used to evaluate the single-exon CNVs detected by Atlas-CNV (Table 2) .
Initially, 29 single-exon CNVs were selected for testing from the 79 candidates described 
DISCUSSION
Prior studies have demonstrated successful CNV detection in DNA sequence data generated from gene panels, but the burden of analyzing single-exon CNVs is a challenge because of high false-positive rates 5, 6 . Recently developed tools such as CoNVaDING 10 and modified versions of ExomeDepth 11, 12 , have been designed to identify single-exon CNVs, but lack quality metrics that enable differentiation of different levels of confidence. As a result, clinical laboratories may often ignore single-exon CNVs. Here, we introduced Atlas-CNV, a fast and accurate CNV calling method based on read depth that report confidence scores for each CNV event that are used to reduces FPs. Previously established methods often fail to account for target variability arising from extremes of DNA sequence coverage, while Atlas-CNV implements multiple strategies to cope with these variabilities. Thus, Atlas-CNV's advantage over other similar methods is the ability to screen or prioritize for high confidence single-exon CNVs. Atlas-CNV also overcomes the limitation of using log2 scores as the sole criteria to detect calls. Furthermore, while existing methods 5,10 have also shown high sensitivity and specificity for detecting single exons in targeted sequence data, our method does not require additional control samples, prior knowledge of model parameters, nor empirical assessments of specific panel designs 11, 13 . These necessities render additional calibrations and can significantly increase costs.
Since Atlas-CNV and VisCap are integral components of the eMERGESeq program, we compared the two and our results showed 90% agreement for large or multi-exonic variants. However, given VisCap's lack of exon filtering, it is difficult to interpret the 39% (or 625/1599) of calls missed by Atlas-CNV for single-exon variants. Furthermore, visual inspection as recommended by VisCap would be a cumbersome task. Therefore, we evaluated the single-exon CNVs with comparison to CoNVaDING calls and conclude Atlas-CNV only missed 4 calls (0.6% or 4/685). We report favorable mean Atlas-CNV C-scores (7.11) and EStDev (0.11) for the 286 common calls even though 57% (164/286) fail the abs(C-score) >8, EStDev <=0.1 criteria. Interestingly, CoNVaDING missed 10 calls that were called by Atlas-CNV (met the abs(C-score) >8, EStDev <=0.1). Thus, this highlights the performance of Atlas-CNV and its ability to prioritize CNV calls to control the FDR and reducing the need for expensive and labor-intensive downstream analysis or assessment.
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